<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34878558</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-1289</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>62</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Der Internist</Title>
          <ISOAbbreviation>Internist (Berl)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[What is confirmed in the treatment of autoinflammatory fever diseases?].</ArticleTitle>
        <Pagination>
          <StartPage>1280</StartPage>
          <EndPage>1289</EndPage>
          <MedlinePgn>1280-1289</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00108-021-01220-9</ELocationID>
        <Abstract>
          <AbstractText>In the last 20 years the clarification of monogenic periodic febrile diseases has led to the independent concept of autoinflammation. In this heterogeneous group polygenic complex diseases are also now included. The spectrum of symptoms is continuously growing. The main difference to autoimmunity is an excessive activation of the innate immune system without formation of autoantibodies or antigen-specific T‑cells. The cardinal symptom is recurrent fever episodes accompanied by signs of inflammation, which in the periodic manifestations alternate with intervals of general well-being. The classical monogenic diseases are also known as hereditary recurrent fever (HRF). Examples are familial Mediterranean fever (FMF), cryopyrin-associated periodic syndrome (CAPS), tumor necrosis factor receptor 1‑associated periodic syndrome (TRAPS), adenosine deaminase 2 (ADA2) deficiency and mevalonate kinase deficiency (MKD, hyper-IgD syndrome). The polygenic diseases are also known as nonhereditary fever syndromes. These include adult-onset Still's disease (AoSD), Adamantiades-Behçet disease, the PFAPA syndrome (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis) and gouty arthritis. All autoinflammatory fever syndromes are accompanied by a long-term risk of development of amyloid A amyloidosis, depending on the individual severity and treatment success. In some diseases severe complications can sometimes occur.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pankow</LastName>
            <ForeName>Anne</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Medizinische Klinik mit Schwerpunkt Rheumatologie und klinische Immunologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Abteilung für Nieren- und Hochdruckerkrankungen, Ambulanz für seltene entzündliche Systemerkrankungen mit Nierenbeteiligung, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feist</LastName>
            <ForeName>Eugen</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Klinik für Rheumatologie, Helios Fachklinik Vogelsang-Gommern, Sophie-von-Boetticher-Str. 1, 39245, Vogelsang, Deutschland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baumann</LastName>
            <ForeName>Ulrich</ForeName>
            <Initials>U</Initials>
            <AffiliationInfo>
              <Affiliation>Klinik für Pädiatrische Pneumologie, Allergologie und Neonatologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kirschstein</LastName>
            <ForeName>Martin</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Klinik für Pädiatrie, AKH Celle, Siemenspatz. 4, 29223, Celle, Deutschland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Burmester</LastName>
            <ForeName>Gerd-Rüdiger</ForeName>
            <Initials>GR</Initials>
            <AffiliationInfo>
              <Affiliation>Medizinische Klinik mit Schwerpunkt Rheumatologie und klinische Immunologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wagner</LastName>
            <ForeName>Annette Doris</ForeName>
            <Initials>AD</Initials>
            <AffiliationInfo>
              <Affiliation>Abteilung für Nieren- und Hochdruckerkrankungen, Ambulanz für seltene entzündliche Systemerkrankungen mit Nierenbeteiligung, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland. Wagner.Annette@mh-hannover.de.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>ger</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>Was ist gesichert in der Therapie von autoinflammatorischen Fiebererkrankungen?</VernacularTitle>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Internist (Berl)</MedlineTA>
        <NlmUniqueID>0264620</NlmUniqueID>
        <ISSNLinking>0020-9554</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000685">Serum Amyloid A Protein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C000718787">AA amyloidosis</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010505" MajorTopicYN="Y">Familial Mediterranean Fever</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005334" MajorTopicYN="N">Fever</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056660" MajorTopicYN="Y">Hereditary Autoinflammatory Diseases</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000685" MajorTopicYN="N">Serum Amyloid A Protein</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherAbstract Type="Publisher" Language="ger">
        <AbstractText>In den letzten 20 Jahren hat die Aufklärung von monogenetisch verursachten periodischen Fiebererkrankungen zum eigenständigen Konzept der Autoinflammation geführt. In diese heterogene Gruppe werden inzwischen auch polygenetisch verursachte, komplexe Erkrankungen eingruppiert. Das Spektrum der Krankheitsbilder wächst kontinuierlich. Hauptunterschied zur Autoimmunität ist eine übermäßige Aktivierung des angeborenen Immunsystems ohne Autoantikörperbildung oder antigenspezifische T‑Zellen. Als Kardinalsymptom treten rezidivierende Fieberschübe, begleitet von Entzündungszeichen, auf; diese wechseln sich bei den periodischen Krankheitsbildern mit Intervallen allgemeinen Wohlbefindens ab. Die klassischen monogenetischen Erkrankungen werden auch als hereditäres rezidivierendes Fieber (HRF) bezeichnet. Beispiele sind das familiäre Mittelmeerfieber (FMF), das Cryopyrin-assoziierte periodische Syndrom (CAPS), das Tumor-Nekrose-Faktor-Rezeptor-1-assoziierte periodische Syndrom (TRAPS), die Adenosindesaminase(ADA2)-Defizienz und die Mevalonatkinasedefizienz (MKD; Hyper-IgD-Syndrom). Die polygenetischen Erkrankungen werden auch als nichthereditäre Fiebersyndrome bezeichnet. Hierzu zählen die adulte Form der Still-Erkrankung („adult-onset Still’s disease“, AoSD), die Adamantiades-Behçet-Erkrankung, das PFAPA-Syndrom (periodisches Fieber, aphthöse Stomatitis, Pharyngitis und zervikale Adenitis) und die Gichtarthritis. Alle autoinflammatorischen Fiebersyndrome gehen mit einem von individuellem Schweregrad und Therapieerfolg abhängigen Langzeitrisiko für die Entwicklung einer Amyloid-A-Amyloidose einher. Bei einigen Erkrankungen können z. T. schwere Komplikationen auftreten.</AbstractText>
        <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation>
      </OtherAbstract>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Adult-onset Stillʼs disease</Keyword>
        <Keyword MajorTopicYN="N">Autoinflammation</Keyword>
        <Keyword MajorTopicYN="N">Familial Mediterranean fever</Keyword>
        <Keyword MajorTopicYN="N">Heriditary periodic fever syndromes</Keyword>
        <Keyword MajorTopicYN="N">Inflammasomopathies</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>8</Day>
          <Hour>12</Hour>
          <Minute>25</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34878558</ArticleId>
        <ArticleId IdType="pmc">PMC8653393</ArticleId>
        <ArticleId IdType="doi">10.1007/s00108-021-01220-9</ArticleId>
        <ArticleId IdType="pii">10.1007/s00108-021-01220-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Orphanet  . Immundefekt, kombinierter schwerer, durch Adenosin-Desaminase-Mangel. 2013. </Citation>
        </Reference>
        <Reference>
          <Citation>Akar S, Cetin P, Kalyoncu U, et al.  Nationwide experience with off-label use of interleukin-1 targeting treatment in familial mediterranean fever patients. Arthritis Care Res. 2018;70:1090–1094. doi: 10.1002/acr.23446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acr.23446</ArticleId>
            <ArticleId IdType="pubmed">28992387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ben-Chetrit E, Touitou I. Familial mediterranean fever in the world. Arthritis Rheum. 2009;61:1447–1453. doi: 10.1002/art.24458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.24458</ArticleId>
            <ArticleId IdType="pubmed">19790133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caorsi R, Penco F, Grossi A, et al.  ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis. 2017;76:1648–1656. doi: 10.1136/annrheumdis-2016-210802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2016-210802</ArticleId>
            <ArticleId IdType="pubmed">28522451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carter SJ, Tattersall RS, Ramanan AV. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology. 2019;58:5–17. doi: 10.1093/rheumatology/key006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/key006</ArticleId>
            <ArticleId IdType="pubmed">29481673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diesinger C, Schriever J. Colchicin – gut informieren, vorsichtig dosieren. Bull Arzneimittelsich. 2017;4:15–23.</Citation>
        </Reference>
        <Reference>
          <Citation>Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med. 2005;201:1355–1359. doi: 10.1084/jem.20050640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20050640</ArticleId>
            <ArticleId IdType="pmc">PMC2213199</ArticleId>
            <ArticleId IdType="pubmed">15867089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol. 2018;14:603–618. doi: 10.1038/s41584-018-0081-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41584-018-0081-x</ArticleId>
            <ArticleId IdType="pmc">PMC7097309</ArticleId>
            <ArticleId IdType="pubmed">30218025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feist E, Quartier P, Fautrel B, et al.  Efficacy and safety of canakinumab in patients with Still’s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol. 2018;36:668–675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29533755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaggiano C, Vitale A, Obici L, Merlini G, Soriano A, Viapiana O, Cattalini M, Maggio MC, Lopalco G, Montin D, Jaber MA, Dagna L, Manna R, Insalaco A, Piga M, La Torre F, Berlengiero V, Gelardi V, Ciarcia L, Emmi G, Ruscitti P, Caso F, Cimaz R, Hernández-Rodríguez J, Parronchi P, Sicignano LL, Verrecchia E, Iannone F, Sota J, Grosso S, Salvarani C, Frediani B, Giacomelli R, Mencarelli MA, Renieri A, Rigante D, Cantarini L. Clinical features at onset and genetic characterization of pediatric and adult patients with TNF-alpha receptor-associated periodic syndrome (TRAPS): a series of 80 cases from the AIDA network. Mediators Inflamm. 2020 doi: 10.1155/2020/8562485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2020/8562485</ArticleId>
            <ArticleId IdType="pmc">PMC7428902</ArticleId>
            <ArticleId IdType="pubmed">32831641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hazenberg BP, van Rijswijk MH. Clinical and therapeutic aspects of AA amyloidosis. Baillieres Clin Rheumatol. 1994;8:661–690. doi: 10.1016/S0950-3579(05)80121-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0950-3579(05)80121-9</ArticleId>
            <ArticleId IdType="pubmed">7954868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hentgen V, Vinit C, Fayand A, et al.  The use of interleukine-1 inhibitors in familial mediterranean fever patients: a narrative review. Front Immunol. 2020;11:971. doi: 10.3389/fimmu.2020.00971.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.00971</ArticleId>
            <ArticleId IdType="pmc">PMC7326122</ArticleId>
            <ArticleId IdType="pubmed">32670263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hofheinz K, Schett G, Manger B. Adult onset Still’s disease associated with malignancy - cause or coincidence? Semin Arthritis Rheum. 2016;45:621–626. doi: 10.1016/j.semarthrit.2015.10.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semarthrit.2015.10.003</ArticleId>
            <ArticleId IdType="pubmed">26581485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kallinich T, Blank N, Braun T, et al.  Evidence-based treatment recommendations for familial Mediterranean fever. A joint statement by the society for pediatric and adolescent rheumatology and the German society for rheumatology. Z Rheumatol. 2019;78:91–101. doi: 10.1007/s00393-018-0588-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00393-018-0588-1</ArticleId>
            <ArticleId IdType="pubmed">30684030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaneko Y, Kameda H, Ikeda K, et al.  Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018;77:1720–1729. doi: 10.1136/annrheumdis-2018-213920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2018-213920</ArticleId>
            <ArticleId IdType="pubmed">30279267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaneko Y, Takeuchi T. Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still’s disease. Expert Opin Biol Ther. 2021 doi: 10.1080/14712598.2021.1942832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14712598.2021.1942832</ArticleId>
            <ArticleId IdType="pubmed">34126828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kedor C, Feist E. Adult-onset Still’s disease: new developments in diagnostics and treatment. Akt Rheumatol. 2017;42:37–45. doi: 10.1055/s-0042-118879.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0042-118879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kedor C, Listing J, Zernicke J, et al.  Canakinumab for treatment of adult-onset Still’s disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis. 2020;79:1090–1097. doi: 10.1136/annrheumdis-2020-217155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2020-217155</ArticleId>
            <ArticleId IdType="pmc">PMC7392486</ArticleId>
            <ArticleId IdType="pubmed">32404342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuemmerle-Deschner JB, Gautam R, George AT, et al.  Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome. RMD Open. 2020;6(2):e001227. doi: 10.1136/rmdopen-2020-001227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/rmdopen-2020-001227</ArticleId>
            <ArticleId IdType="pmc">PMC7722275</ArticleId>
            <ArticleId IdType="pubmed">32723831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lachmann HJ, Goodman HJ, Gilbertson JA, et al.  Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–2371. doi: 10.1056/NEJMoa070265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa070265</ArticleId>
            <ArticleId IdType="pubmed">17554117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lainka E, Neudorf U, Lohse P, et al.  Incidence of TNFRSF1A mutations in German children: epidemiological, clinical and genetic characteristics. Rheumatology (Oxford) 2009;48:987–991. doi: 10.1093/rheumatology/kep140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/kep140</ArticleId>
            <ArticleId IdType="pubmed">19541728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Langevitz P, Zemer D, Livneh A, et al.  Protracted febrile myalgia in patients with familial Mediterranean fever. J Rheumatol. 1994;21:1708–1709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7799354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee PY, Kellner ES, Huang Y, et al.  Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2) J Allergy Clin Immunol. 2020;145:1664–1672.e10. doi: 10.1016/j.jaci.2019.12.908.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2019.12.908</ArticleId>
            <ArticleId IdType="pmc">PMC7282972</ArticleId>
            <ArticleId IdType="pubmed">31945408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leone F, Cerasuolo PG, Bosello SL, et al.  Adult-onset Still’s disease following COVID-19 vaccination. Lancet Rheumatol. 2021;3:e678–e680. doi: 10.1016/S2665-9913(21)00218-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2665-9913(21)00218-6</ArticleId>
            <ArticleId IdType="pmc">PMC8298028</ArticleId>
            <ArticleId IdType="pubmed">34316728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Y, Meng J, Jia J, et al.  Current and emerging biological therapy in adult-onset Still’s disease. Rheumatology (Oxford) 2021;60:3986–4000. doi: 10.1093/rheumatology/keab485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/keab485</ArticleId>
            <ArticleId IdType="pmc">PMC8410009</ArticleId>
            <ArticleId IdType="pubmed">34117886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magliulo D, Narayan S, Ue F, et al.  Adult-onset Still’s disease after mRNA COVID-19 vaccine. Lancet Rheumatol. 2021;3:e680–e682. doi: 10.1016/S2665-9913(21)00219-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2665-9913(21)00219-8</ArticleId>
            <ArticleId IdType="pmc">PMC8298008</ArticleId>
            <ArticleId IdType="pubmed">34316726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malcova H, Strizova Z, Milota T, et al.  IL-1 inhibitors in the treatment of monogenic periodic fever syndromes: from the past to the future perspectives. Front Immunol. 2020;11:619257. doi: 10.3389/fimmu.2020.619257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.619257</ArticleId>
            <ArticleId IdType="pmc">PMC7884884</ArticleId>
            <ArticleId IdType="pubmed">33603750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masters SL, Simon A, Aksentijevich I, et al.  Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*) Annu Rev Immunol. 2009;27:621–668. doi: 10.1146/annurev.immunol.25.022106.141627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.immunol.25.022106.141627</ArticleId>
            <ArticleId IdType="pmc">PMC2996236</ArticleId>
            <ArticleId IdType="pubmed">19302049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meyts I, Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol. 2018;38:569–578. doi: 10.1007/s10875-018-0525-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-018-0525-8</ArticleId>
            <ArticleId IdType="pmc">PMC6061100</ArticleId>
            <ArticleId IdType="pubmed">29951947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mukhin NA, Kozlovskaya LV, Bogdanova MV, et al.  Predictors of AA amyloidosis in familial Mediterranean fever. Rheumatol Int. 2015;35:1257–1261. doi: 10.1007/s00296-014-3205-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-014-3205-x</ArticleId>
            <ArticleId IdType="pubmed">25586652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Njonnou SRS, Soyfoo MS, Vandergheynst FA. Efficacy of sarilumab in adult-onset Still’s disease as a corticosteroid-sparing agent. Baillieres Clin Rheumatol. 2019;58:1878–1879.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31056689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozen S, Demirkaya E, Erer B, et al.  EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75:644–651. doi: 10.1136/annrheumdis-2015-208690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2015-208690</ArticleId>
            <ArticleId IdType="pubmed">26802180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez-Smith J, Lin YC, Tsai WL, et al.  Cerebrospinal fluid cytokines correlate with aseptic meningitis and blood-brain barrier function in neonatal-onset multisystem inflammatory disease: central nervous system Biomarkers in neonatal-onset Multisystem inflammatory disease correlate with central nervous system inflammation. Arthritis Rheumatol. 2017;69:1325–1336. doi: 10.1002/art.40055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.40055</ArticleId>
            <ArticleId IdType="pmc">PMC5449229</ArticleId>
            <ArticleId IdType="pubmed">28118536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savic S, Dickie LJ, Battellino M, et al.  Familial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases. Curr Opin Rheumatol. 2012;24:103–112. doi: 10.1097/BOR.0b013e32834dd2d5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/BOR.0b013e32834dd2d5</ArticleId>
            <ArticleId IdType="pubmed">22089100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schepp J, Proietti M, Frede N, et al.  Screening of 181 patients with antibody deficiency for deficiency of adenosine deaminase 2 sheds new light on the disease in adulthood. Arthritis Rheumatol. 2017;69:1689–1700. doi: 10.1002/art.40147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.40147</ArticleId>
            <ArticleId IdType="pubmed">28493328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sfriso P, Bindoli S, Doria A, et al.  Canakinumab for the treatment of adult-onset Still’s disease. Expert Rev Clin Immunol. 2020;16:129–138. doi: 10.1080/1744666X.2019.1707664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/1744666X.2019.1707664</ArticleId>
            <ArticleId IdType="pubmed">31957508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sibley CH, Plass N, Snow J, et al.  Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum. 2012;64:2375–2386. doi: 10.1002/art.34409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.34409</ArticleId>
            <ArticleId IdType="pmc">PMC3474541</ArticleId>
            <ArticleId IdType="pubmed">22294344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomaras S, Goetzke CC, Kallinich T, et al.  Adult-onset still’s disease: clinical aspects and therapeutic approach. J Clin Med. 2021;10:733. doi: 10.3390/jcm10040733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm10040733</ArticleId>
            <ArticleId IdType="pmc">PMC7918550</ArticleId>
            <ArticleId IdType="pubmed">33673234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tufan A, Lachmann HJ. Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review. Turk J Med Sci. 2020;50:1591–1610. doi: 10.3906/sag-2008-11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3906/sag-2008-11</ArticleId>
            <ArticleId IdType="pmc">PMC7672358</ArticleId>
            <ArticleId IdType="pubmed">32806879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Hilst J, Moutschen M, Messiaen PE, et al.  Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics. 2016;10:75–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4831592</ArticleId>
            <ArticleId IdType="pubmed">27110096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zemer D, Pras M, Sohar E, et al.  Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med. 1986;314:1001–1005. doi: 10.1056/NEJM198604173141601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM198604173141601</ArticleId>
            <ArticleId IdType="pubmed">3515182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Q, Yang D, Ombrello AK, et al.  Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370:911–920. doi: 10.1056/NEJMoa1307361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1307361</ArticleId>
            <ArticleId IdType="pmc">PMC4193683</ArticleId>
            <ArticleId IdType="pubmed">24552284</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
